Compare Virgin Galactic Holdings, Inc. (SPCE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.78 (market cap $329.06M), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 370.6× Virgin Galactic Holdings, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| SPCE | VRTX | |
|---|---|---|
Market Cap | $329.06M | $121.95B |
Sector | Industrials | Health |
52-Week High | $7.52 | $529.59 |
52-Week Low | $2.17 | $366.54 |
Enterprise Value | $428.90M | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCE trades at $2.78, up 8.59% in the last session, but remains in a bearish technical trend with negative cash flows and deep losses. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with profitability metrics deeply negative. Recent news highlights volatility tied to space sector sentiment and SpaceX's market activities, contributing to sharp price swings.
The outlook is highly speculative with significant execution and funding risks. While analyst ratings are mixed, the lack of revenue scale and persistent cash burn pose substantial challenges. Investment potential hinges on successful commercialization, but current fundamentals do not support a sustainable valuation, making it suitable only for high-risk investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
